Superworth

Arcturus Therapeutics price to free cash flow ARCT

Market value divided by free cash flow over the last twelve months, since 2023.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
56.7×
Aug 2024
Peer median
11.0×

Arcturus Therapeutics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Aug 2024, at 56.7×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
202456.7×6.1×107×
20236.2×3.9×30.3×

Against its peers

Companies in Drug Manufacturers - General nearest Arcturus Therapeutics' size, closest first, today.

CompanyPrice to free cash flow
ARCTArcturus Therapeuticsn/m
NATRNatures Sunshine Products11.8×
ARVNArvinasn/m
PBYIPuma Biotechnology13.8×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics17.9×
CRMDCorMedix2.4×
COLLCollegium Pharmaceutical2.3×
ABUSArbutus Biopharman/m
LFVNLifevantage11.0×
AMPHAmphastar Pharmaceuticals7.0×
Peer median11.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Arcturus Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.